1-19 of 19
Keywords: Peptide receptor radionuclide therapy
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Neuroendocrinology 1–14.
Published Online: 03 December 2024
... was to profile the peripheral blood transcriptome through RNA-Seq and investigate the association of the systemic cancer hallmarks with progression-free survival, in peptide receptor radionuclide therapy (PRRT)-treated GEP-NET patients. Methods: The cohorts were discovery cohort [PRRT-naïve well-differentiated...
Journal Articles
Journal Articles
Neuroendocrinology (2023) 113 (3): 281–288.
Published Online: 07 March 2023
... Pavlakis Hormonal crises are a rare but increasingly recognized phenomenon following peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms (NENs). Due to the paucity of published studies, approaches to the identification, prevention, and management of risk factors...
Journal Articles
Journal Articles
Neuroendocrinology (2022) 112 (1): 43–50.
Published Online: 18 January 2021
... = 50) and pNET ( n = 20). Plasma cfDNA levels were determined by droplet digital PCR for the beta-2-microglobulin gene every 6 months during a period of 3 years, including in a subgroup of 19 patients during peptide receptor radionuclide therapy (PRRT) therapy. Results: cfDNA levels were higher in both...
Journal Articles
Journal Articles
Neuroendocrinology (2021) 111 (9): 863–875.
Published Online: 18 September 2020
... neuroendocrine tumours (PNET) was analysed separately. These patients had received 234 lines of treatment (105 chemotherapy, 82 molecular targeted therapy, and 47 peptide receptor radionuclide therapy [PRRT]). In the G2 cohort, TTF and TTP were superior for PRRT compared with both chemotherapy and molecular...
Journal Articles
Neuroendocrinology (2021) 111 (4): 344–353.
Published Online: 08 April 2020
... indicated radiation-induced damage to the pituitary gland as a probable cause. 177 Lu-DOTATATE Peptide receptor radionuclide therapy Pituitary Radiotherapy Neuroendocrine tumor Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE is an approved treatment for metastatic...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Neuroendocrinology (2017) 105 (3): 295–309.
Published Online: 13 April 2017
... The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use...
Journal Articles
Journal Articles
Journal Articles
Journal Articles